{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-006243","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.760270+00:00","generated_at":"2026-06-27T05:32:27.996730+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulgent Genetics Q4 revenue $251.7M, full year 2021 revenue $992.6M, core revenue up 236% YoY","bullets":["Q4 revenue $251.7M; full year 2021 revenue $992.6M, up 135% year-over-year.","Core revenue (ex-COVID) rose 234% YoY to $40.1M in Q4; full year core rev $122.6M (+236%).","GAAP net income $104.3M ($3.34 EPS) in Q4; full year GAAP net income $507.4M ($16.38 EPS).","Non-GAAP income $108.7M ($3.48 EPS) in Q4; adjusted EBITDA $159.8M.","Cash, cash equivalents & marketable securities $935.5M as of Dec 31, 2021; cash from ops $77.1M in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-006243","json":"https://secwatch.observer/filing/0001564590-22-006243.json","markdown":"https://secwatch.observer/filing/0001564590-22-006243.md","text":"https://secwatch.observer/filing/0001564590-22-006243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000156459022006243/0001564590-22-006243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000156459022006243/flgt-8k_20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:32:27.996730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}